lipella.com (LIPO): Net earnings per share growth forecast for next year
The current valuation of Lipella Pharmaceuticals (LIPO) EPS growth for the coming year reflects the clinical testing stage of liposomal agents, where portfolio expansion necessitates a proportional increase in spending. The value of 0.00 represents the latest metric reading. The business relies on a fabless model, minimizing capital expenditures and collecting royalties from industry behemoths. However, the urology segment is experiencing rigorous selection and pressure from affordable generics.
Lipella Pharmaceuticals, Inc. (LIPO) - metric breakdowns and financial figures
- share price and consensus valuation forecast:
- stock exchange capitalization data:
- company book value details:
- company total debt and liquidity indicators:
Debt to Equity Lipella Pharmaceuticals|LIPO - Long-Term Liabilities to Equity|Short-Term Debt to Capital lipella.com|LIPO - Company Cumulative Debt|Debt to Book Capitalization Ratio Lipella Pharmaceuticals Inc|LIPO - Company Long-Term Debt|Company Short-Term Debt Lipella Pharmaceuticals|Quick Ratio lipella.com
- net income and valuation ratios data:
LIPO - Net Profit|Future Profit Lipella Pharmaceuticals|LIPO - Company Value to Net Income|Future Price to Earnings Lipella Pharmaceuticals|LIPO - Market Cap to Earnings and Growth Ratio|EV/EBITDA Multiple Lipella|LIPO - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Lipella Pharmaceuticals|LIPO - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months lipella.com|LIPO - Earnings per share increase in current year|Net earnings per share growth forecast for next year Lipella Pharmaceuticals
- company sales and revenue statistics:
Fundamental company analysis:LIPO, Lipella Pharmaceuticals
Lipella Pharmaceuticals' development of urological drugs is independent of economic cycles; therefore, the trend in the company's forward EPS estimates reflects solely the success of molecular clinical trials. This indicator measures the consensus growth forecast for earnings for the coming year, allowing investors to assess the asset's capitalization potential through expected earnings per share amid the macroeconomic resilience of the biotech sector.
Key competitors
Net earnings per share growth forecast for next year Haleon plc|Expected net earnings per share growth next year kenvue.com KVUE|Net earnings per share growth forecast for next year Verona Pharma (VRNA)|MENS (Jyong Biotech Limited) - Expected earnings per share trend next year|Net earnings per share growth forecast for next year Ligand Pharma LGND|Earnings growth forecast for next year Amneal Corp AMRX|Perrigo Company PLC - Earnings growth forecast for next year|ALVO: Net earnings per share growth forecast for next year|liquidia.com (LQDA) - Net earnings per share growth forecast for next year|GLPG (Galapagos) - Net earnings per share growth forecast for next year|Expected earnings per share growth for next year ANIP|Projected earnings per share growth rate for next year MNKD (Afrezza)|Earnings growth forecast for next year AMPH|PCRX (Pacira BioSciences) - Expected earnings per share trend next year|Earnings growth forecast for next year SPRY (ARS Pharmaceuticals, Inc.)|Theravance Biopharma, Inc. - Net earnings per share growth forecast for next year|Aquestive Corp - Earnings growth forecast for next year|scpharmaceuticals.com (SCPH) - Expected earnings per share growth for next year|TECX: Earnings growth forecast for next year|Tonix Pharmaceuticals - Expected earnings per share trend next year|Expected earnings per share growth for next year SXTC|EPRX: Expected earnings per share trend next year|Expected earnings per share growth for next year BHST (BioHarvest Sciences Inc.)|Consensus forecast of earnings per share growth for next year Invizyne|Net earnings per share growth forecast for next year Oramed Pharmaceuticals ORMP|Expected earnings per share trend next year ENTX|HYFT - Net earnings per share growth forecast for next year|Expected earnings per share trend next year ABVC (ABVC BioPharma Inc.)|CPIX: Earnings growth forecast for next year|Quantum BioPharma Limited - Expected earnings per share trend next year|FGEN (FibroGen Corp) - Earnings growth forecast for next year|Earnings growth forecast for next year Telomir Pharmaceuticals|Earnings growth forecast for next year RANI|SNYR (Synergy CHC Corp.) - Expected earnings per share trend next year|Earnings growth forecast for next year RLYB (Rallybio Corp)|LEXX: Projected earnings per share growth rate for next year|PULM - Net earnings per share growth forecast for next year|PTHL: Net earnings per share growth forecast for next year|APM (aptorumgroup.com) - Expected earnings per share growth for next year|Lyra Therapeutics - Expected earnings per share trend next year|Net earnings per share growth forecast for next year Impact BioMedical Inc|TNF Pharmaceuticals, Inc. (TNFA) - Consensus forecast of earnings per share growth for next year|Earnings growth forecast for next year YCBD|PRFX: Net earnings per share change forecast for next year|Net earnings per share growth forecast for next year altamiratherapeutics.com CYTO|Expected earnings per share trend next year OPTN|PIRS - Net earnings per share growth forecast for next year|Procaps Group Corp (PROC) - Expected earnings per share growth for next year|Petros (PTPI) - Net earnings per share growth forecast for next year|Net earnings per share change forecast for next year QLI (Qilian International)|Expected earnings per share growth for next year SLRN|TFF Pharmaceuticals, Inc. - Net earnings per share change forecast for next year
